KR20140034150A - 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물 - Google Patents

시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20140034150A
KR20140034150A KR1020137023105A KR20137023105A KR20140034150A KR 20140034150 A KR20140034150 A KR 20140034150A KR 1020137023105 A KR1020137023105 A KR 1020137023105A KR 20137023105 A KR20137023105 A KR 20137023105A KR 20140034150 A KR20140034150 A KR 20140034150A
Authority
KR
South Korea
Prior art keywords
gne
leu
ile
val
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137023105A
Other languages
English (en)
Korean (ko)
Inventor
대니얼 다비쉬
야디라 볼즈-아유브
Original Assignee
에이치아이비엠 리서치 그룹, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이치아이비엠 리서치 그룹, 인코포레이티드 filed Critical 에이치아이비엠 리서치 그룹, 인코포레이티드
Priority to KR1020197026529A priority Critical patent/KR102257741B1/ko
Publication of KR20140034150A publication Critical patent/KR20140034150A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137023105A 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물 Ceased KR20140034150A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020197026529A KR102257741B1 (ko) 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
US61/438,585 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026529A Division KR102257741B1 (ko) 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20140034150A true KR20140034150A (ko) 2014-03-19

Family

ID=46603295

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137023105A Ceased KR20140034150A (ko) 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물
KR1020197026529A Active KR102257741B1 (ko) 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197026529A Active KR102257741B1 (ko) 2011-02-01 2012-02-01 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물

Country Status (9)

Country Link
US (2) US20130030040A1 (cg-RX-API-DMAC7.html)
EP (2) EP3202425A1 (cg-RX-API-DMAC7.html)
JP (2) JP2014506787A (cg-RX-API-DMAC7.html)
KR (2) KR20140034150A (cg-RX-API-DMAC7.html)
AU (2) AU2012212162A1 (cg-RX-API-DMAC7.html)
CA (1) CA2863578C (cg-RX-API-DMAC7.html)
IL (1) IL227773B (cg-RX-API-DMAC7.html)
MX (1) MX365095B (cg-RX-API-DMAC7.html)
WO (1) WO2012106465A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
AU2001236739A1 (en) * 2000-02-08 2001-08-20 Genentech Inc. Improved sialylation of glycoproteins
US20060218669A1 (en) * 2003-02-11 2006-09-28 Lokesh Joshi Sialylation of glycoproteins in plants
US20070073264A1 (en) * 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
JP5415283B2 (ja) * 2007-02-07 2014-02-12 グラダリス インク． シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
WO2008124934A1 (en) 2007-04-17 2008-10-23 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US9018174B2 (en) * 2008-05-28 2015-04-28 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
CA2736488A1 (en) 2008-09-09 2010-03-18 The Regents Of The University Of California Elimination of a contaminating non-human sialic acid by metabolic competition
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content

Also Published As

Publication number Publication date
IL227773B (en) 2021-03-25
CA2863578C (en) 2021-10-26
JP2017158577A (ja) 2017-09-14
AU2017203027A1 (en) 2017-07-20
EP2670442A4 (en) 2015-07-29
MX2013008948A (es) 2014-02-18
EP2670442A2 (en) 2013-12-11
AU2017203027B2 (en) 2019-08-15
US20140275230A1 (en) 2014-09-18
EP3202425A1 (en) 2017-08-09
CA2863578A1 (en) 2012-08-09
AU2012212162A1 (en) 2013-08-29
KR102257741B1 (ko) 2021-05-28
US20130030040A1 (en) 2013-01-31
KR20190108178A (ko) 2019-09-23
IL227773A0 (en) 2013-09-30
WO2012106465A3 (en) 2014-04-24
WO2012106465A2 (en) 2012-08-09
US10098969B2 (en) 2018-10-16
JP2014506787A (ja) 2014-03-20
MX365095B (es) 2019-05-22

Similar Documents

Publication Publication Date Title
KR102257741B1 (ko) 시알산 생성을 증가시키고 시알릭 관련 질환 병증을 치료하기 위한 방법 및 조성물
AU2020205228B2 (en) Gene therapies for lysosomal disorders
AU2018207259B2 (en) Polynucleotides and vectors for the expression of transgenes
KR102609858B1 (ko) 점액다당류증의 치료를 위한 아데노-관련 바이러스 벡터
CN108495685B (zh) 针对艰难梭菌感染的基于酵母的免疫疗法
KR20220006527A (ko) 리소좀 장애에 대한 유전자 요법
US20230149566A1 (en) Compositions and methods for treating macular dystrophy
CA3158428A1 (en) Cortical neural progenitor cells from ipscs
CN106591371A (zh) Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
AU2019388876A1 (en) IL-2 Dependent NK-92 cells with stable Fc receptor expression
KR20230051529A (ko) 리소좀 장애에 대한 유전자 요법
CA2945240A1 (en) Transgenic pig islets and uses thereof for treating diabetes
AU2016252887B2 (en) Smad7 gene delivery as a therapeutic
KR20220112283A (ko) Hunter 질환 치료용 아데노-연합된 바이러스 벡터
CN115916985A (zh) 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
KR102065917B1 (ko) Glb1 유전자를 발현하는 형질전환된 줄기세포 및 이를 포함하는 gm1 강글리오시드증 치료용 약학 조성물
CN111961651A (zh) 基因重组PD-1抗体自分泌型人γδT细胞及其构建方法和应用
CN110819589B (zh) 一种增强免疫效应细胞功能的方法
KR101557974B1 (ko) 혈청형６ 재조합 아데노바이러스 제조용 벡터
CN110124024B (zh) 一种新城疫基因vii型dna纳米颗粒疫苗及制备及应用
CN116926123A (zh) 自复制mRNA增强型TIL细胞及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130830

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180530

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20190605

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20190605

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20190429

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20180830

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190909